A higher dietary ratio of long-chain omega-3 to total omega-6 fatty acids for prevention of COX-2-dependent adenocarcinomas

Nutrition and Cancer

Volumn 66, Issue 8, 2014, Pages 1279-1284

  Dinicolantonio, James J ^a   McCarty, Mark F ^b   Chatterjee, Subhankar ^c   Lavie, Carl J ^d,e   Okeefe, James H ^a,f  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b Catalytic Longevity   (United States)

^c R G KAR MEDICAL COLLEGE   (India)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Center   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROSTAGLANDIN E2; PROSTAGLANDIN E3; VITAMIN D; PTGS2 PROTEIN, HUMAN;

ADENOCARCINOMA; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; COLORECTAL CANCER; DIET SUPPLEMENTATION; DIETARY INTAKE; ENDOMETRIUM CANCER; FISH MEAT; FOOD INTAKE; HUMAN; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; TUMOR PROMOTION; ANALYSIS; CLINICAL TRIAL (TOPIC); METABOLISM; RISK FACTOR; SEA FOOD;

ADENOCARCINOMA; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIETARY SUPPLEMENTS; DINOPROSTONE; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-6; FISH OILS; HUMANS; RISK FACTORS; SEAFOOD;

EID: 84911432299     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.956262     Document Type: Article

References (77)

1. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, et al.: Cyclooxygenase-2 and gastric carcinogenesis. APMIS 111, 915-925, 2003.
2. Piazuelo E, Jimenez P, and Lanas A: COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr Pharm Des 9, 2267-2280, 2003.
3. Glover JA, Hughes CM, Cantwell MM, and Murray LJ: A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer 105, 13-17, 2011.
4. Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, et al.: Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 31, 4359-4367, 2011.
5. Ohno S, Ohno Y, Suzuki N, Inagawa H, Kohchi C, et al.: Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res 25, 3679-3687, 2005.
6. Kraus S, Naumov I, and Arber N: COX-2 active agents in the chemoprevention of colorectal cancer. Recent Results Cancer Res 191, 95-103, 2013.
7. Sandler AB and Dubinett SM: COX-2 inhibition and lung cancer. Semin Oncol 31, 45-52, 2004.
8. Hussain T, Gupta S, and Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191, 125-135, 2003.
9. Moran EM: Epidemiological and clinical aspects of nonsteroidal antiinflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 21, 193-201, 2002.
10. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, et al.: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31-41, 2011.
11. Tosco P and Lazzarato L: Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. ChemMedChem 4, 939-945, 2009.
12. Chan AT, Ogino S, and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356, 2131-2142, 2007.
13. Chan AT, Ogino S, and Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649-658, 2009.
14. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, et al.: Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47-55, 2005.
15. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, et al.: Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128, 713-720, 1998.
16. Chun KS, Akunda JK, and Langenbach R: Cyclooxygenase-2 inhibits UVB-induced apoptosis in mouse skin by activating the prostaglandin E2 receptors, EP2 and EP4. Cancer Res 67, 2015-2021, 2007.
17. Chu AJ, Chou TH, and Chen BD: Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front Biosci 9, 2697-2713, 2004.
18. Wu T, Leng J, Han C, and Demetris AJ: The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3, 299-307, 2004.
19. Mutoh M, Takahashi M, and Wakabayashi K: Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention. Curr Pharm Des 12, 2375-2382, 2006.
20. Wang D and DuBois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31, 64-73, 2004.
21. Wendum D, Masliah J, Trugnan G, and Flejou JF: Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 445, 327-333, 2004.
22. Dempke W, Rie C, Grothey A, and Schmoll HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127, 411-417, 2001.
23. Greenhough A, Wallam CA, Hicks DJ, Moorghen M, Williams AC, et al.: The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene 29, 3398-3410, 2010.
24. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, et al.: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2, 632-642, 2004.
25. Lin DW and Nelson PS. The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer 2, 119-126, 2003.
26. Sun Y, Tang XM, Half E, Kuo MT, and Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62, 6323-6328, 2002.
27. Schulte-Hermann R, Bursch W, Kraupp-Grasl B, Oberhammer F, and Wagner A. Programmed cell death and its protective role with particular reference to apoptosis. Toxicol Lett 64-65, 569-574, 1992.
28. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, et al.: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140, 27-35, 1999.
29. Diaz-Cruz ES, Shapiro CL, and Brueggemeier RW: Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90, 2563-2570, 2005.
30. Subbaramaiah K, Hudis C, Chang SH, Hla T, and Dannenberg AJ: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 283, 3433-3444, 2008.
31. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Get al.: Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2, 356-365, 2012.
32. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, et al.: Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 4, 329-346, 2011.
33. Rose DP and Vona-Davis L: Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors 40, 1-12, 2013.
34. Martinez-Gonzalez J and Badimon L: Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 13, 2215-2227, 2007.
35. McCarty MF: Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention. Med Hypotheses 78, 45-57, 2012.
36. Fragiskos B, Chan AC, and Choy PC: Competition of n-3 and n-6 polyunsaturated fatty acids in the isolated perfused rat heart. Ann Nutr Metab 30, 331-334, 1986.
37. Garg ML, Sebokova E, Thomson AB, and Clandinin MT: Delta 6-desaturase activity in liver microsomes of rats fed diets enriched with cholesterol and/or omega 3 fatty acids. Biochem J 249, 351-356, 1988.
38. Gronn M, Christensen E, Hagve TA, and Christophersen BO: Effects of dietary purified eicosapentaenoic acid (20: 5 (n-3)) and docosahexaenoic acid (22: 6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells. Biochim Biophys Acta 1125, 35-43, 1992.
39. Lands WE, Libelt B, Morris A, Kramer NC, Prewitt TE, et al.: Maintenance of lower proportions of (n-6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n-3) fatty acids. Biochim Biophys Acta 1180, 147-162, 1992.
40. Vecchio AJ, Simmons DM, and Malkowski MG: Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem 285, 22152-22163, 2010.
41. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, et al.: Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas 36, 353-362, 2008.
42. Calder PC: n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions. Proc Nutr Soc 72, 326-336, 2013.
43. West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, et al.: Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 59, 918-925, 2010.
44. Bartram HP, Gostner A, Scheppach W, Reddy BS, Rao CV, Dusel G, Richter F, Richter A, Kasper H. Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology 105: 1317-1322, 1993.
45. Bartram HP, Gostner A, Reddy BS, Rao CV, Scheppach W, et al.: Missing anti-proliferative effect of fish oil on rectal epithelium in healthy volunteers consuming a high-fat diet: potential role of the n-3: n-6 fatty acid ratio. Eur J Cancer Prev 4, 231-237, 1995.
46. Fabian CJ and Kimler BF. Marine-derived omega-3 Fatty acids. Am Soc Clin Oncol Educ Book 97-101, 2013.
47. Fernandez E, Chatenoud L, La VC, Negri E, and Franceschi S: Fish consumption and cancer risk. Am J Clin Nutr 70, 85-90, 1999.
48. Terry P, Wolk A, Vainio H, and Weiderpass E: Fatty fish consumption lowers the risk of endometrial cancer: a nationwide case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 11, 143-145, 2002.
49. Jedrychowski W, Maugeri U, Pac A, Sochacka-Tatara E, and Galas A: Protective effect of fish consumption on colorectal cancer risk. Hospitalbased case-control study in Eastern Europe. Ann Nutr Metab 53, 295-302, 2008.
50. Fong LY, Ho JH, and Huang DP: Preserved foods as possible cancer hazards: WA rats fed salted fish have mutagenic urine. Int J Cancer 23, 542-546, 1979.
51. Stich HF, Chan PK, and Rosin MP: Inhibitory effects of phenolics, teas and saliva on the formation of mutagenic nitrosation products of salted fish. Int J Cancer 30, 719-724, 1982.
52. Gonzalez CA, Sanz JM, Marcos G, Pita S, Brullet E, et al.: Dietary factors and stomach cancer in Spain: a multi-centre case-control study. Int J Cancer 49, 513-519, 1991.
53. Jakszyn P and Gonzalez CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol 12, 4296-4303, 2006.
54. Ren ZF, Liu WS, Qin HD, Xu YF, Yu DD, et al.: Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong, China. Cancer Epidemiol 34, 419-424, 2010.
55. Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, et al.: Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 17, 4421-4428, 2011.
56. Ye WM, Yi YN, Luo RX, Zhou TS, Lin RT, et al.: Diet and gastric cancer: a casecontrol study in Fujian Province, China. World J Gastroenterol 4, 516-518, 1998.
57. Takezaki T, Inoue M, Kataoka H, Ikeda S, Yoshida M, et al.: Diet and lung cancer risk from a 14-year population-based prospective study in Japan: with special reference to fish consumption. Nutr Cancer 45, 160-167, 2003.
58. Stott-Miller M, Neuhouser ML, and Stanford JL: Consumption of deepfried foods and risk of prostate cancer. Prostate 73, 960-969, 2013.
59. Joshi AD, John EM, Koo J, Ingles SA, and Stern MC: Fish intake, cooking practices, and risk of prostate cancer: results from a multi-ethnic casecontrol study. Cancer Causes Control 23, 405-420, 2012.
60. He K, Xun P, Brasky TM, Gammon MD, Stevens J, et al.: Types of fish consumed and fish preparation methods in relation to pancreatic cancer incidence: the VITAL Cohort Study. Am J Epidemiol 177, 152-160, 2013.
61. Ansorena D, Guembe A, Mendizabal T, and Astiasaran I: Effect of fish and oil nature on frying process and nutritional product quality. J Food Sci 75, H62-H67, 2010.
62. Strobel C, Jahreis G, and Kuhnt K: Survey of n-3 and n-6 polyunsaturated fatty acids in fish and fish products. Lipids Health Dis 11, 144, 2012.
63. Zhang XM, Wakabayashi K, Liu ZC, Sugimura T, and Nagao M: Mutagenic and carcinogenic heterocyclic amines in Chinese cooked foods. Mutat Res 201, 181-188, 1988.
64. Liu XL: [Genotoxicity of fried fish extract, MeIQ and inhibition by green tea antioxidant]. Zhonghua Zhong Liu Za Zhi 12, 170-173, 1990.
65. Khan MR, Busquets R, Saurina J, Hernandez S, and Puignou L: Identification of seafood as an important dietary source of heterocyclic amines by chemometry and chromatography-mass spectrometry. Chem Res Toxicol 26, 1014-1022, 2013.
66. Skog KI, Johansson MA, and Jagerstad MI: Carcinogenic heterocyclic amines in model systems and cooked foods: a review on formation, occurrence and intake. Food Chem Toxicol 36, 879-896, 1998.
67. Hamilton MC, Hites RA, Schwager SJ, Foran JA, Knuth BA, et al.: Lipid composition and contaminants in farmed and wild salmon. Environ Sci Technol 39, 8622-8629, 2005.
68. Karapanagiotidis IT, Bell MV, Little DC, Yakupitiyage A, and Rakshit SK: Polyunsaturated fatty acid content of wild and farmed tilapias in Thailand: effect of aquaculture practices and implications for human nutrition. J Agric Food Chem 54, 4304-4310, 2006.
69. Young K: Omega-6 (n-6) and omega-3 (n-3) fatty acids in tilapia and human health: a review. Int J Food Sci Nutr 60(Suppl 5), 203-211, 2009.
70. Kantor ED, Lampe JW, Peters U, Vaughan TL, and White E. Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. Nutr Cancer 66, 716-727, 2013.
71. Brasky TM, Lampe JW, Potter JD, Patterson RE, and White E: Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiol Biomarkers Prev 19, 1696-1708, 2010.
72. Brasky TM, Kristal AR, Navarro SL, Lampe JW, Peters U, et al.: Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort. Nutr Cancer 63, 573-582, 2011.
73. Torfadottir JE, Valdimarsdottir UA, Mucci LA, Kasperzyk JL, Fall K, Tet al.: Consumption of fish products across the lifespan and prostate cancer risk. PLoS ONE 8, e59799, 2013.
74. Szymanski KM, Wheeler DC, and Mucci LA: Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 92, 1223-1233, 2010.
75. Arem H, Neuhouser ML, Irwin ML, Cartmel B, Lu L, et al.: Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a populationbased case-control study. Eur J Nutr 52, 1251-1260, 2013.
76. Bell GA, Kantor ED, Lampe JW, Kristal AR, Heckbert SR, et al.: Intake of long-chain omega-3 fatty acids from diet and supplements in relation to mortality. Am J Epidemiol 179, 710-720, 2014.
77. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, et al.: The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33, 159-171, 2012.